Buprenorphine extended-release implant (Probuphine; Braeburn Pharmaceuticals Inc.) for opioid use disorder
HAYES, Inc
Record ID 32018000010
English
Authors' recommendations:
Patients with opioid use disorder may benefit from medication-assisted treatments that include a combination of medication and behavioral therapy.
Technology Description:
Probuphine is an implantable system containing buprenorphine hydrochloride, which is an opioid partial agonist drug intended to ease symptoms of withdrawal and opioid cravings. The implantable system allows for
extended release of the drug.
Patient Population:
Probuphine is intended for treatment of opioid dependence in patients who have achieved and maintained low-to-moderate daily doses of sublingual buprenorphine.
Clinical Alternatives:
Alternatives to Probuphine that are appropriate for outpatient use include sublingual or oral buprenorphine, sublingual buprenorphine-naloxone, oral methadone, and oral naltrexone
Details
Project Status:
Completed
Year Published:
2017
URL for published report:
The report may be purchased from:
http://www.hayesinc.com/hayes/crd/?crd=72646
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Buprenorphine
- Humans
- Narcotic Antagonists
- Opioid-Related Disorders
- Pharmaceutical Preparations
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.